13F Holdings
中文EN

PEPG PepGen Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1835597 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY21.6%
TTM EPS YoY72.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-55.1%
ROA-46.1%
ROIC (approx.)-121.4%
Asset turnover—

Leverage & solvency

Liabilities / assets19.3%
Debt / equity0.00x
Current ratio8.70x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.86x
Accruals ratio-6.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$71.04M$76.48M$68.13M$54.08M$19.00M
SG&A expense$22.57M$21.26M$16.64M$14.22M$8.11M
Operating income-$93.61M-$97.74M-$84.77M-$68.30M-$27.11M
Pretax income-$89.61M-$90.60M-$78.55M-$65.40M-$27.28M
Income tax$48,865-$617,000$73,000$3.70M$0
Net income-$89.66M-$89.98M-$78.63M-$69.10M-$27.28M
EBITDA-$92.21M-$96.24M-$83.57M-$67.80M-$26.91M
EPS (basic)-2.12-2.85-3.30-4.42-30.27
EPS (diluted)-2.12-2.85-3.30-4.42-30.27
Weighted avg. shares (diluted)42.22M31.58M23.80M15.64M901,108
Balance sheet
Cash & equivalents$60.51M$49.42M$80.77M$181.75M$132.90M
Short-term investments$87.94M$70.77M$29.63M$0—
Current assets$150.96M$123.76M$112.68M$186.08M$139.99M
PP&E, net$1.90M$3.72M$4.76M$3.33M$636,000
Total assets$173.91M$150.88M$143.05M$217.44M$143.64M
Current liabilities$12.65M$16.70M$17.53M$18.83M$10.32M
Total liabilities$26.46M$32.26M$34.63M$37.81M$10.55M
Shareholders' equity$147.44M$118.62M$108.42M$179.63M-$32.08M
Shares outstanding68.87M32.62M23.82M23.71M963,588
Cash flow statement
Operating cash flow-$81.64M-$82.37M-$69.00M-$59.27M-$22.60M
Capital expenditure$264,000$497,000$2.60M$3.75M$500,000
Free cash flow-$81.90M-$82.87M-$71.60M-$63.02M-$23.10M
Investing cash flow-$15.23M-$37.67M-$32.00M-$3.75M-$500,000
Financing cash flow$107.98M$88.75M-$189,000$112.19M$147.66M
Depreciation & amortization$1.40M$1.50M$1.20M$500,000$200,000
Stock-based compensation$10.61M$11.46M$7.05M$4.76M$1.53M

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.